Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,656 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Growth Clear all
Completed No phase listed Observational Accepts healthy volunteers

Snoring in Pregnancy and Adverse Maternal and Fetal Outcomes

NCT01030003
View directory record Official record
Conditions
Sleep Apnea Syndromes
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
1,685 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

NCT05549505
View directory record Official record
Conditions
Breast Cancer
Interventions
ARV-471, Anastrozole, Surgical resection of breast tumor
Drug · Procedure
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 23, 2026, 8:51 AM EDT
Completed No phase listed Observational

USCOM in Newly Diagnosed FGR Cases

NCT06343051
View directory record Official record
Conditions
Fetal Growth Restriction, USCOM
Interventions
USCOM
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Early Phase 1 Interventional

Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates

NCT00517062
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Growth hormone (Genotropin), Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Phase 2Phase 3 Interventional

Dextrose Gel Does Not Prevent Neonatal Hypoglycemia

NCT02523222
View directory record Official record
Conditions
Hypoglycemia, Infant, Small for Gestational Age, Premature Birth of Newborn, Fetal Macrosomia, Intrauterine Growth Restriction, Complication of Prematurity, Neonatal Hypoglycemia
Interventions
40% Dextrose gel
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Hours to 1 Hour
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)

NCT01525901
View directory record Official record
Conditions
22q13 Deletion Syndrome, Phelan-McDermid Syndrome
Interventions
Insulin-Like Growth Factor-1 (IGF-1), Normal saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
5 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 23, 2026, 8:51 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

MRI in BPD Subjects

NCT03657693
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
NICU MRI, Polysomnography
Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 4 Months
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Not applicable Interventional

Influence of Adiposity on IGF-1 and Fitness Response to Exercise in Cancer Survivors

NCT05558384
View directory record Official record
Conditions
Cancer, Overweight and Obesity
Interventions
Aerobic Exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 79 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 23, 2026, 8:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

NCT00807612
View directory record Official record
Conditions
Advanced Squamous Non-Small Cell Lung Cancer
Interventions
AMG 479, Carboplatin, Paclitaxel
Biological · Drug
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Fayetteville, Arkansas • Fort Wayne, Indiana • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

NCT02766699
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Grade IV
Interventions
EGFR(V)-EDV-Dox
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Not applicable Interventional Results available

Physiologic Growth Hormone Effects in HIV Lipodystrophy

NCT00100698
View directory record Official record
Conditions
AIDS, HIV Infections
Interventions
recombinant human growth hormone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Phase 3 Interventional

Dose Comparison of Amino Acids on Growth in Premature Neonates

NCT00120926
View directory record Official record
Conditions
Malnutrition
Interventions
Parenteral Nutrition
Drug
Lead sponsor
Pediatrix
Other
Eligibility
0 Years to 48 Hours
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Florence, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2006 · Synced Oct 23, 2026, 8:51 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Minipuberty of Infancy and the Timing of Pubertal Development in Adolescence: a Follow-up of the Infant Feeding and Early Development (IFED) Cohort

NCT05463120
View directory record Official record
Conditions
Puberty
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
8 Years to 100 Years
Enrollment
566 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 8:51 AM EDT
Completed No phase listed Observational

The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation

NCT00056784
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Not applicable Interventional

Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)

NCT00108225
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LoBag Diet - test phase, LoBAG Diet - control phase
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
55 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Phase 3 Interventional

Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature

NCT00191074
View directory record Official record
Conditions
Growth Disorder
Interventions
somatropin, rDNA origin, for injection
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
9 Years to 16 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2007 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Not applicable Interventional

Prospective Nail Polish Study

NCT05181761
View directory record Official record
Conditions
Bacterial Growth
Interventions
Gel Polish
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutritional Stimulation of Growth in Children With Short Stature

NCT04226586
View directory record Official record
Conditions
Nutritional Stunting, Growth Failure
Interventions
Essential Amino Acid (EAA) group, Placebo
Dietary Supplement
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
3 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 23, 2026, 8:51 AM EDT
Not listed No phase listed Observational

Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy

NCT04724083
View directory record Official record
Conditions
Fabry
Interventions
biomarkers
Diagnostic Test
Lead sponsor
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 23, 2026, 8:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Bottle Optimization Testing Tiny Little Eaters Study

NCT07665983
View directory record Official record
Conditions
Childhood Obesity
Interventions
Feeding
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
4 Months and older
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer

NCT00034541
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
cetuximab, paclitaxel, carboplatin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
3
States / cities
Denver, Colorado • Greenwich, Connecticut • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 9, 2010 · Synced Oct 23, 2026, 8:51 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

NCT01450696
View directory record Official record
Conditions
Gastric Cancer
Interventions
Capecitabine, Cisplatin, Herceptin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • Whittier, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neuroimaging Study of Exercise and Memory Function

NCT02057354
View directory record Official record
Conditions
Aging
Interventions
Aerobic Exercise, Non-Aerobic Exercise
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years to 85 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 23, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

NCT02697773
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 23, 2026, 8:51 AM EDT